Jeff Albers, Blueprint CEO

Blue­print Med­i­cines nabs 4th ap­proval in bid to­ward prof­itabil­i­ty

Blue­print Med­i­cines’ push to prof­itabil­i­ty con­tin­ues.

On Wednes­day, the Cam­bridge biotech an­nounced the FDA ap­proved its long­time lead drug, Ay­vak­it, for ad­vanced sys­temic mas­to­cy­to­sis, a group of de­bil­i­tat­ing rare dis­eases where one type of im­mune cell — mast cells — builds up un­con­trol­lably in a par­tic­u­lar or­gan. The de­ci­sion came on the heels of Phase III tri­als show­ing that more than half of late-stage pa­tients who re­ceived the drug re­spond­ed to it and did so for just over three years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.